Avestar Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Avestar Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-750	Closed	-$44K	–	251
2019 Q2	$44K	Buy	750 +202	+37%	+$17.3K	0.03%	308
2019 Q1	$27K	Sell	548 -25	-4%	-$2.32K	0.02%	351
2018 Q4	$28K	Sell	573 -34	-6%	-$3.23K	0.02%	307
2018 Q3	$38K	Buy	607 +66	+12%	+$6.59K	0.02%	299
2018 Q2	$32K	Buy	541 +525	+3,281%	+$46K	0.02%	312
2018 Q1	$1K	Buy	+16	New	+$1.37K	﹤0.01%	692

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Avestar Capital's BMRN Position: Q3 2019 in Review

Avestar Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 750 shares — an estimated $44K sold.

Avestar Capital first reported a position in BMRN in Q1 2018 and held it in 6 quarters. The position peaked at $44K in Q2 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Avestar Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Avestar Capital sold 750 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $44K.
Avestar Capital first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Avestar Capital's BioMarin Pharmaceuticals position peaked at $44K in Q2 2019.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.